Zivo Bioscience Files 8-K
Ticker: ZIVOW · Form: 8-K · Filed: Sep 10, 2025 · CIK: 1101026
| Field | Detail |
|---|---|
| Company | Zivo Bioscience, Inc. (ZIVOW) |
| Form Type | 8-K |
| Filed Date | Sep 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
TL;DR
ZIVO filed an 8-K on 9/10/25 with financial updates.
AI Summary
Zivo Bioscience, Inc. filed an 8-K on September 10, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as Health Enhancement Products Inc. and Western Glory Hole Inc., is incorporated in Nevada and operates in the biological products sector.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and exhibits, which provides updates on the company's operational and financial status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material events or changes.
Key Players & Entities
- Zivo Bioscience, Inc. (company) — Registrant
- September 10, 2025 (date) — Date of Report
- Health Enhancement Products Inc. (company) — Former Company Name
- Western Glory Hole Inc. (company) — Former Company Name
- Nevada (jurisdiction) — State of Incorporation
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report under Regulation FD and to include financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on September 10, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Zivo Bioscience, Inc.
In which state is Zivo Bioscience, Inc. incorporated?
Zivo Bioscience, Inc. is incorporated in Nevada.
What were some of Zivo Bioscience, Inc.'s former company names?
Zivo Bioscience, Inc.'s former company names include Health Enhancement Products Inc. and Western Glory Hole Inc.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-09-10 09:49:23
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ZIVO OTCQB Warrants to p
Filing Documents
- zivo_8k.htm (8-K) — 27KB
- zivo_ex991.htm (EX-99.1) — 25KB
- 0001654954-25-010579.txt ( ) — 185KB
- zivo-20250910.xsd (EX-101.SCH) — 5KB
- zivo-20250910_lab.xml (EX-101.LAB) — 15KB
- zivo-20250910_cal.xml (EX-101.CAL) — 1KB
- zivo-20250910_pre.xml (EX-101.PRE) — 11KB
- zivo-20250910_def.xml (EX-101.DEF) — 5KB
- zivo_8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Zivo Bioscience, Inc. (the "Company") today issued a press release containing a letter to shareholders from CEO John Payne. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated here by reference. A copy of the press release is also available via the Company's website at https://ir.zivobioscience.com/. Materials on the Company's website are not part of or incorporated by reference into this report. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the ExchangeAct, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated September 10, 2025 104 Cover Page Interactive Data File (embedded within the XBRL document ) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZIVO BIOSCIENCE, INC. By: /s/ Keith Marchiando Keith Marchiando Chief Financial Officer Date: September 10, 2025 3